Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease

Journal of Clinical Immunology

Volumn 31, Issue 3, 2011, Pages 323-331

  Wasserman, Richard L ^a   Melamed, Isaac ^b   Kobrynski, Lisa ^c   Strausbaugh, Steven D ^d   Stein, Mark R ^e   Sharkhawy, Marlies ^f   Engl, Werner ^f   Leibl, Heinz ^f   Sobolevsky, Luba ^g   Gelmont, David ^g   Schiff, Richard I ^g   Grossman, William J ^g  

^a Pediatric Allergy/Immunology Associates   (United States)

^b 1st Allergy and Clinical Research Center ^*  (United States)

^c Emory Children's Center   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e Allergy Associates of the Palm Beaches   (United States)

^f BAXTER INNOVATIONS GMBH   (Austria)

^g BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

efficacy; pharmacokinetic comparison; primary immunodeficiency disease; Subcutaneous immunoglobulin; tolerability

Indexed keywords

IMMUNOGLOBULIN;

AREA UNDER THE CURVE; ARTICLE; ASTHMA; BACTERIAL INFECTION; BIOEQUIVALENCE; CHILD; CLINICAL ARTICLE; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INFECTION RISK; INJECTION SITE REACTION; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NIJIMEN CHROMOSOME BREAKAGE SYNDROME; PHARYNX DISEASE; PRESCHOOL CHILD; PRIMARY IMMUNODEFICIENCY DISEASE; PRIORITY JOURNAL; RISK REDUCTION; SCHOOL CHILD; UPPER ABDOMINAL PAIN; VOMITING; X LINKED AGAMMAGLOBULINEMIA;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; BACTERIA; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; COMMON VARIABLE IMMUNODEFICIENCY; DRUG TOXICITY; FEMALE; GENETIC DISEASES, X-LINKED; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KINETICS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOLUTIONS; TREATMENT OUTCOME; UNITED STATES;

EID: 79961169672     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9512-z     Document Type: Article

References (27)

1. A Gardulf 2007 Immunoglobulin treatment for primary antibody deficiencies. Advantages of the subcutaneous route Biodrogs 21 2 105 116 10.2165/00063030-200721020-00005 1:CAS:528:DC%2BD2sXmtVCnu74%3D (Pubitemid 46624555)
2. HM Chapel GP Spickett D Ericson W Engl MM Eibl J Björkander 2000 The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy J Clin Immunol 20 2 94 100 10821460 10.1023/A:1006678312925 1:CAS:528:DC%2BD3cXjvVClsro%3D (Pubitemid 30314313)
3. M Berger 2002 A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies Curr Allergy Asthma Rep 2 5 368 378 12165202 10.1007/s11882-002-0069-z
4. HD Ochs S Gupta P Kiessling, et al. 2006 Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases J Clin Immunol 26 265 273 16783465 10.1007/s10875-006-9021-7 1:CAS:528:DC%2BD28XlvVOks7c%3D (Pubitemid 43901655)
5. A Gardulf U Nicolay O Asensio, et al. 2006 Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-A prospective multi-national study J Clin Immunol 26 177 185 16758340 10.1007/s10875-006-9002-x 1:CAS:528:DC%2BD28XltlOisrg%3D (Pubitemid 43869918)
6. S Radinsky VR Bonagura 2003 Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin J Allergy Clin Immunol 112 3 630 633 13679829 10.1016/S0091-6749(03)01781-0 1:CAS:528:DC%2BD3sXovVyktbc%3D (Pubitemid 37108574)
7. JJ Roord JW van der Meer W Kuis, et al. 1982 Home treatment in patients with antibody deficiency by slow subcutaneous infusion of gammaglobulin Lancet 1 689 690 6175862 1:STN:280:DyaL387nt1Sgsw%3D%3D (Pubitemid 12179950)
8. U Nicolay P Kiessling M Berger, et al. 2006 Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home J Clin Immunol 26 1 65 72 16418804 10.1007/s10875-006-8905-x 1:CAS:528: DC%2BD28XltVSguw%3D%3D (Pubitemid 43112626)
9. A Gardulf U Nicolay O Asensio, et al. 2004 Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home J Allergy Clin Immunol 114 4 936 942 15480339 10.1016/j.jaci.2004.06.053 1:CAS:528:DC%2BD2cXotlClt7s%3D (Pubitemid 39330270)
10. S Hansen R Gustafson CIE Smith A Gardulf 2002 Express subcutaneous IgG infusions: decreased time of delivery with maintained safety Clin Immmunol 104 3 237 241 10.1006/clim.2002.5215 1:CAS:528:DC%2BD38XosF2ktr4%3D (Pubitemid 35191099)
11. A Fasth J Nyström 2008 Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin J Clin Immunol 28 4 370 378 18256911 10.1007/s10875-008-9180-9 1:CAS:528:DC%2BD1cXot1WksL8%3D
12. IUIS Scientific Committee 1999 Primary immunodeficiency diseases: report of an IUIS Scientific Committee Clin Exp Immunol 118 Suppl 1 1 28
13. H Dette KF Pilz 2006 A comparative study of monotone nonparametric kernel estimates J Statist Comp Simul 76 41 56 10.1080/00949650412331321061 (Pubitemid 43078559)
14. Food and Drug Administration and Center for Biologics Evaluation and Research. Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency (Draft Guidance). 2005. U.S. Department of Health and Human Services, Food and Drug Administration (FDA).
15. RL Wasserman 2010 Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease Clin Exp Immunol 161 518 526 20550549 10.1111/j.1365-2249.2010.04195.x 1:CAS:528:DC%2BC3cXhtFOku7%2FE
16. J Hagan 2010 Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20 in patients with primary immunodeficiency J Clin Immunol 30 734 745 20454851 10.1007/s10875-010-9423-4 1:CAS:528:DC%2BC3cXhtFamurnL
17. JA Church H Leibl MR Stein, et al. 2006 Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin (IGIV 10%) in patients with primary immunodeficiency J Clin Immunol 26 4 388 395 16705486 10.1007/s10875-006-9025-3 1:CAS:528:DC%2BD28XmvVaqtrk%3D (Pubitemid 44051386)
18. MR Stein RP Nelson JA Church, et al. 2009 Safety and efficacy of privigen®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies J Clin Immunol 29 1 137 144 18814020 10.1007/s10875-008-9231-2 1:CAS:528:DC%2BD1MXht1Ohsbo%3D
19. J Björkander J Nikoskelainen H Leibl, et al. 2006 Prospective open-labeled study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia Vox Sang 90 286 293 16635071 10.1111/j.1423-0410.2006.00764.x
20. CM Roifman H Schroeder M Berger, et al. 2003 Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial Int Immunopharmacol 3 9 1325 1333 12890430 10.1016/S1567-5769(03)00134-6 1:CAS:528:DC%2BD3sXlvVGru7s%3D (Pubitemid 36936768)
21. HD Ochs PJ Pinciaro and the Octagam Study Group 2004 Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency disease J Clin Immunol 24 3 309 314 15114062 10.1023/B:JOCI.0000025453.23817.3f 1:CAS:528:DC%2BD2cXjsVOisrY%3D (Pubitemid 39030679)
22. HW Eijkhout JWM van der Meer CGM Kallenberg RS Weening JT van Dissel LAM Sanders PFW Strengers H Nienhuis PTA Schellekens 2001 The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia Ann Intern Med 135 3 165 174 11487483 1:CAS:528:DC%2BD3MXmtlWktrw%3D (Pubitemid 32738310)
23. J Orange WJ Grossman RJ Navickis MM Wilkes 2010 Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies Clin Immunol 137 1 21 30 20675197 10.1016/j.clim.2010.06.012 1:CAS:528:DC%2BC3cXhtFyisrzO
24. J Siegel 2005 The product: all intravenous immunoglobulin are not equivalent Pharmacotherapy 25 11 pt 2 78S 84 16229678 10.1592/phco.2005.25. 11part2.78S 1:CAS:528:DC%2BD2MXht1GhsrnL (Pubitemid 41566908)
25. EW Gelfand 2006 Differences between IGIV products: impact on clinical outcomes Int Immunopharmacol 6 4 592 599 16504921 10.1016/j.intimp.2005.11.003 1:CAS:528:DC%2BD28Xhslyrs7o%3D
26. Octapharma AG - Update: Product Withdrawal/Product Recall - Octagam (Octagam 50 mg/ml) and Octagam 10% (Octagam 100 mg/ml). Octapharma AG, 2010. http://www.octapharma.com/about-octapharma/news-events/news-single-view/news/ update-product-withdrawalproduct-recall-octagam-octagam-50mgml-and-octagam-10- octagam-100mg.html. Last accessed 23 NOV 2010.
27. CSL Behring. Vivaglobin. Immune Globulin Subcutaneous (Human), US Label. April 2007.